Manufacturing News

Osteopore to establish first global centre of excellence at Singaporean hospital

Manufacturing News

Australian-Singaporean bioresorbable implants manufacturer Osteopore has announced a partnership with SingHealth to establish the company’s first Global Centre of Excellence (GCoE) for customised medical devices. 

The company said in an ASX statement on Tuesday that its wholly-owned Singaporean subsidiary, Osteopore International Pte Ltd, signed the non-exclusive Partnership Agreement with SingHealth, which it is  expected to conclude in H2 2026.  

According to the announcement, the new GCoE would enable the company to “set up a dedicated workspace on SGH Campus to co-develop, test, validate, adopt and scale its customised medical device globally” as well as to work with clinicians at the hospital. This is under the auspices of Alice Lee Innovation Centre of Excellence at Singapore General Hospital Campus (also known as A.L.I.C.E@SGH Campus.)

In parallel to the partnership, Ostepore has also appointed three SGH clinicians to its advisory panel.

“I’m delighted to solidify Osteopore’s partnership with SingHealth and to cement our presence on the SGH Campus to support the global expansion plans of our customised medical device,” said Osteopore CEO Dr Yujing Lim.

“With SGH-based clinicians on our Advisory Panel, we look forward to their contributions to our GCoE. SGH was ranked the number one Academic Medical Centre (AMC) in East Asia – and placed 8th globally – by Brand Finance in the Global Top 250 Hospitals 2023 Report.”

Osteopore said it was being assisted through Enterprise Singapore – an agency within the Ministry of Trade and Industry – through an Enterprise Development Grant covering “up to 70% of qualifying costs.” This would be applied to a partnership fee of S$284,485 (approximately $320,000) payable by OSX monthly over 30 months.

Osteopore’s bioresorbable bone scaffolds are used in conjunction with surgery to assist with bone healing.

The products are made from a polymer called polycaprolactone (PCL) and slowly degrade away in the body as natural bone and tissue replace them.

Picture: credit Osteopore

Further reading

Osteopore to purchase distribution businesses

Osteopore regenerative implants to join Protheses List

Osteopore receives approval to sell 3D printed bone scaffolds

Osteopore 3D shines on debut

Share this Story
Manufacturing News

Stay Informed

Go to Top